Wednesday, August 27, 2014

TearLab to unveil second generation tear testing platform

TearLab to unveil second generation tear testing platform

August 14, 2014 by · Leave a Comment 

Tweet At its analyst and investor day on Sept. 23, TearLab (NASDAQ:TEAR; TSX:TLB) plans to cover its current business and growth strategies, international market opportunities recent R&D activities, including development of a second-generation point-of-care tear testing platform. On the second quarter conference call earlier this month, CEO Elias Vamvaskas said most of the research has been […]

TearLab Q2 revenue climbs 42%

TearLab Q2 revenue climbs 42%

August 7, 2014 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) has reported second quarter revenue of $5-million, up 42% from $3.5-million in the year earlier quarter and an increase of 19% sequentially from $4.2-million in the 2014 first quarter. A net 171 TearLab Osmolarity systems were added to the company’s installed base in the second quarter. Of those, 126 systems were […]

TearLab, Cancer Genetics in Feltl’s Top Idea List for H2-2014

TearLab, Cancer Genetics in Feltl’s Top Idea List for H2-2014

July 8, 2014 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) and Cancer Genetics (NASDAQ:CGIX) have been included in Feltl & Co.’s Top Ideal List for the second half of 2014. Analyst Ben Haynor rates both stocks as “strong buys.” His price target for TearLab is $10.50 and $18.50 for Cancer Genetics. He said TearLab has first-mover advantage in point-of-care diagnostics for […]

Mati Therapeutics gets another U.S. patent

Mati Therapeutics gets another U.S. patent

June 30, 2014 by · Leave a Comment 

Tweet Closely held Mati Therapeutics has received a U.S. patent covering its novel punctal plug delivery system for treatment of ocular indications (PPDS), including certain features for retaining the punctal plug within the nasolacrimal system of the eye during drug elution. The patent is titled, “Nasolacrimal Drainage System Implants For Drug Therapy.” Mati is actively […]

Mati Therapeutics isn’t your traditional biotech startup

Mati Therapeutics isn’t your traditional biotech startup

June 10, 2014 by · Leave a Comment 

Tweet Not quite two years old yet, closely held Mati Therapeutics is conducting a pre-Phase 3 clinical trial with an ocular punctal plug delivery system (PPDS) that could become a preferred alternative to eye drops. “Because of the Phase 2 trials conducted by QLT on this technology, we have a different risk-reward profile than a […]

TearLab posts 70% jump in Q1 revenue

TearLab posts 70% jump in Q1 revenue

May 8, 2014 by · Leave a Comment 

Tweet First quarter revenue for TearLab (NASDAQ:TEAR; TSX:TLB) totaled $4.2-million, up 70%, from $2.5-million a year ago. A total of 254 orders for TearLab systems were booked in the first quarter, of which 201 systems were under the company’s Masters Multi Unit Program, 40 were through its minimum use access programs, six were direct purchases […]

Survey finds high confidence in tear osmolarity testing

Survey finds high confidence in tear osmolarity testing

April 25, 2014 by · Leave a Comment 

Tweet A survey by Ophthalmic Consultants of Long Island conducted after TearLab (NASDAQ:TEAR; TSX:TLB) partnered with major dry eye organization, Sjögren’s Society, to promote Dry Eye Disease Awareness Month last year found a high degree of patient satisfaction in tear osmolarity testing. There were 278 eye clinics that participated in the survey and over 1,000 […]

Alcon’s Paul Smith joins TearLab as VP International

Alcon’s Paul Smith joins TearLab as VP International

April 21, 2014 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) has appointed Paul Smith to its senior management team in the newly created position of VP, International. Mr. Smith’s mandate will be the development and execution of a comprehensive international business strategy for TearLab. He joins TearLab from his current position as global marketing manager within the surgical cataract franchise at […]

TearLab to acquire AOA’s OcuHub platform

TearLab to acquire AOA’s OcuHub platform

February 18, 2014 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) has signed a non-binding term sheet to purchase the assets of the OcuHub business unit from AOAExcel, the for-profit subsidiary of the American Optometric Association (“AOA”). OcuHub, powered by AT&T and Covisint, is an established compliant technology platform designed to securely connect eye doctors, patients, healthcare organizations and payers. The acquisition […]

TearLab issues prelim Q4 revenue and gives 2014 revenue guidance

TearLab issues prelim Q4 revenue and gives 2014 revenue guidance

February 3, 2014 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) said preliminary total revenue for the fourth quarter of 2013 is expected to be about $4.5-million, bringing expected full year 2013 revenue to about $14.7-million.   The preliminary expected revenue in the fourth quarter reflects an increase of about 181%, compared with revenue of $1.6-million in the fourth quarter of 2012. The […]

Next Page »

Email Newsletters with Constant Contact
Google+